Publication

Article

Oncology & Biotech News

January 2011
Volume5
Issue 1

Company Claims to Make Safer Smokeless Tobacco

Star Scientific, a Virginia-based company, has petitioned the FDA to approve the sale of what it claims is a

Star Scientific, a Virginia-based company, has petitioned the FDA to approve the sale of what it claims is a "safer" smokeless tobacco. Stonewall Moist-BDL is a tobacco lozenge that the manufacturer claims contains 90% to 99% less carcinogens than currently marketed smokeless tobacco products. Under the Family Smoking Prevention and Tobacco Control Act passed in 2009, the FDA is authorized to regulate tobacco products, and the company is hoping to receive the "modified risk" label that the FDA is working to develop. Like cigarettes, smokeless tobacco is addictive and considered harmful to human health.

Related Videos
Alec Watson, MD
Balazs Halmos, MD
Balazs Halmos, MD
Suresh Senan, MRCP, FRCR, PhD, full professor, treatment and quality of life, full professor, cancer biology and immunology, full professor, radiation oncology, professor, clinical experimental radiotherapy, Amsterdam University Medical Centers
Alison Schram, MD
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.
Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.